Skip to main content

MICHELE PAU

By

Michele joined Fideres in 2018, and is currently leading our financial litigation practice. Michele has worked on a number of financial projects, spanning from pre-filing to class certification and settlement…

Read More

STEFFEN HENNIG

By

Steffen is a founding partner of Fideres with over 21 years’ experience in structured products and complex derivatives across all major asset classes. Steffen is responsible for the quantitative analysis…

Read More

PROF. ROBERT WEBB

By

Prof Robert Webb is the Martin J. Patsel, Jr., Research Professor at the McIntire School of Commerce at the University of Virginia in Charlottesville, Virginia, U.S.A. He is also the…

Read More

PROF. MYRON GLUCKSMAN

By

Myron Glucksman provides independent expert advice regarding ABS, Conduits, CDOs, RMBS, SIVs and other structured finance matters as well as private label credit card matters Formerly a Managing Director in…

Read More

PROF. LINDA ALLEN

By

Linda Allen is the William F. Aldinger Chair and Presidential Professor of Finance, Zicklin School of Business, Baruch College CUNY. Professor Allen’s research and consulting interests include banking and financial…

Read More

ANDRES BRITO BARREIRO

By

Andres joined Fideres in September 2021 after completing his MSc in Financial Technology at Imperial College Business School with distinction. Prior to that he undertook a Banking and Finance BSc…

Read More

PROF. CAROL ALEXANDER

By

Carol Alexander is Professor of Finance at Sussex University Business School, Visiting Professor at Peking University HSBC Business School and Co-Editor of the Journal of Banking and Finance. Her current…

Read More

ZOHAIB MOONIS

By

Zohaib joined Fideres in 2021 after completing his MS in Quantitative Finance from Fordham University in New York City. Since joining Fideres, he has been involved with the financial and…

Read More

ROUSLAN HALIL

By

Rouslan joined Fideres in November 2020. Since joining, Rouslan has provided analysis for a variety of cases ranging from pharmaceutical antitrust in the US, to portfolio damages in securities litigation…

Read More